Disclosed herein are modified Leishmania species and compositions thereof, such as live, attenuated organisms, immunogenic compositions, vaccines, and pharmaceutical compositions. Further disclosed are methods related to the modified Leishmania species, such as methods of production and methods of use.

An engineered phage-derived particle (PDP) for expressing a transgene in a target cell transduced with a bacteriophage, the PDP includes (i) less than about 500 bp of DNA from the bacteriophage genome, (ii) an ITR-flanked therapeutic gene up to 20 kb, (iii) an endosomal escape sequence, (iv) a nuclear localization sequence, and (v) a cell-specific targeting moiety. The PDP may escape lysosomal degradation, traffic across the nuclear envelope and expressed a therapeutic gene in a mammalian cell.

An object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism. The present invention relates to a microorganism having an ability to produce docosahexaenoic acid (DHA), wherein the microorganism contains a protein composed of an amino acid sequence in which at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 in the amino acid sequence represented by SEQ ID NO: 2 has been substituted with another amino acid residue (mutated OrfB), and is capable of producing eicosapentaenoic acid (EPA), and the like.

An object of the present invention is to provide a microorganism that efficiently produces EPA and a method for producing EPA using the microorganism. The present invention relates to a microorganism having an ability to produce docosahexaenoic acid (DHA), wherein the microorganism contains a protein composed of an amino acid sequence in which at least one of the amino acid residues at positions 6, 65, 230, 231, and 275 in the amino acid sequence represented by SEQ ID NO: 2 has been substituted with another amino acid residue (mutated OrfB), and is capable of producing eicosapentaenoic acid (EPA), and the like.

The present disclosure relates to hydrogels composition comprising protist cells. In particular, the present disclosure relates to hydrogel compositions which may be used to encapsulate or suspend ciliated protist cells, and methods of preparing the same. The present disclosure further relates to methods of infecting molluscs with a ciliated protist cell, and methods and compositions for stabilising ciliated protist cells.

The present invention describes methods of identifying high-risk populations or individuals who have positive serology for T. gondii. These methods include obtaining a biological sample from a subject; determining the level of T. gondii cyst antigen antibody in the biological sample; and characterizing the biological sample in at least one of three categories.

The present invention relates to an oil of microorganisms rich in docosahexaenoic acid (DHA, C22:6n3), comprising more than 60% of DHA relative to the total mass of fat and to the use thereof for human or animal feed, in particular for feeding infants, children, or pregnant or lactating women.

The liquid biological antifungal product containing the Pythium oligandrum microorganism containing a stabilized suspension of the Pythium oligandrum microorganism contains 0.05 to 10.0% weight culturing biomass of the Pythium oligandrum microorganism with content of cultivation medium, cell forms of this microorganism and substances produced by this microorganism and 90.0 to 99.95% weight stabilizer, where-by the pre-determined number of dormant oospores in 1 ml of this liquid biological anti-fungal product is, following normal standardization, between 1×10.sup.3 and 2×10.sup.7. The liquid biological antifungal product containing the Pythium oligandrum microorganism containing a stabilized suspension of the Pythium oligandrum microorganism contains 0.05 to 10.0% weight culturing biomass of the Pythium oligandrum microorganism with content of cultivation medium, cell forms of this microorganism and substances produced by this microorganism; and 79.77 to 99.95% weight stabilizer, and the remainder, up to 100% weight, a minimum of one modifying/application substance from a group including filling, aroma and vitamin; whereby the pre-determined number of dormant oospores in 1 ml of this liquid biological antifungal product is, following normal standardization, between 2.5×10.sup.4 and 1.0×10.sup.6. The Pythium oligandrum microorganism is the Pythium oligandrum Dreschler ATTC 38472 strain, which was deposited in the Czech Collection of Microorganisms (CCM) at Masaryk University in Brno under the appellation of Pythium oligandrum M1. The stabilizer may be water, a salt solution, oil or a concentrated solution of osmolytes. The method of production of this liquid biological antifungal product is claimed.

The present invention is directed to isolated microorganisms as well as strains and mutants thereof, biomasses, microbial oils, compositions, and cultures; methods of producing the microbial oils, biomasses, and mutants; and methods of using the isolated microorganisms, biomasses, and microbial oils.

Described herein are compositions and methods of producing glycosylated proteins in vitro and in vivo. The methods include using host cells to produce glycosylated proteins. Also described herein are glycosylated proteins produced using such methods and uses thereof.